Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Benedictuson Dec 08, 2023 11:33pm
343 Views
Post# 35775991

Financials

Financials
Question for some of the posters here that review the financials:
 
In the LIFE offering they said  they had approximately $1M of working capital as of October 26, 2023.
However, the MD&A shows they had $226,197 in working capital as of Sept 30th. The last cash raise of $460K closed on Sept 7th, so that was already included and there were no additional funds raised until the Nov 29th closing, so the only conclusion I can come to is that they appear to have overstated their working capital by almost $800K in the LIFE offering document. 
 
That additional $800K is roughly 2.5 months of cash runway, which I’d included in my expectation for them to easily get to March/April before needing additional funds. So, unless someone can point out where my calcs are off (I'm all ears...), I’m assuming by the time this latest raise closed they were at negative working capital and the $1.17M raise gives them a lifeline until end of January (using monthly burn of $325K) before needing to push out payables and put out the begging bowl once more, likely in February. Perhaps they will be working furiously to try and get BTD submitted so they can PR that milestone just prior to doing another pp. 
 
<< Previous
Bullboard Posts
Next >>